Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|June 17, 2015

Quintiles Introduces Infosario One Mobile App

RESEARCH TRIANGLE PARK, N.C. – June 16, 2015 – Quintiles,the world’s largest biopharmaceutical services company, is extending its award-winning Quintiles Infosario® technology platform with mobile access to critical clinical trial information. Using the mobile app, key stakeholders in the drug development process can conveniently access site start-up, recruitment and compliance information as well as status updates on data queries and project milestones.

“With so much at stake in the successful delivery of development programs, faster decision making is fundamental,” said Margaret Keegan, senior vice president of Data Sciences & Strategy at Quintiles. “Infosario One provides instant and intuitive access to insights at your fingertips, wherever and whenever you need them.”

The Infosario One mobile app can be personalized with different filters so users can quickly see precisely what’s most important to them. These customized views are then served up in mobile-friendly charts that automatically reflect the latest information. 

“Increasing complexity in the delivery of clinical trials - and the related information overload - can slow down progress or obscure valuable information,” said Alejandro Martinez, chief information officer at Quintiles. “We are committed to innovation that simplifies the complex, so this app provides not just easy access but at-a-glance transparency into study progress.”

The Infosario One mobile app will initially be available for download at the Apple App Store. 

Quintiles’ experts will demo the app at its booth at the upcoming Drug Information Association (DIA) conference June 14-18, 2015 in Washington, D.C. For more information about Quintiles Infosario One, visit the Quintiles booth at DIA (#601) or www.quintiles.com/infosario-one.

 


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.